Bacterial DNA and DNA-processing enzymes (Helicobacter pylori)

Helicobacter pylori (H. pylori) utilizes a specialized set of DNA and DNA-processing enzymes to maintain genomic integrity and facilitate gene expression within the human gastric mucosa. This target group includes DNA gyrase (composed of GyrA and GyrB subunits), which manages DNA supercoiling during replication, and DNA-dependent RNA polymerase, which is responsible for all bacterial transcription (PubMed: 25643118, 22491334). The bacterial DNA itself is also a therapeutic target, particularly for nitroimidazole drugs that induce lethal strand breaks. These processes are fundamental to the survival and virulence of H. pylori, a pathogen directly linked to chronic gastritis, peptic ulcers, and gastric adenocarcinoma (NIH/NIDDK). Antimicrobial agents targeting these systems, such as levofloxacin and metronidazole, are cornerstones of eradication therapy. However, the clinical utility of these drugs is frequently compromised by the rapid development of resistance-conferring mutations in the target enzymes or activating pathways (StatPearls: Helicobacter Pylori).

Other names

H. pylori DNA replication machineryHelicobacter pylori DNA gyraseH. pylori DNA-dependent RNA polymeraseH. pylori genomic DNAHelicobacter pylori DNA-processing enzymes

The mechanism of action involves the inhibition of essential DNA-related processes: fluoroquinolones bind to the DNA-gyrase complex to arrest DNA replication; rifamycins bind to the beta subunit of DNA-dependent RNA polymerase to inhibit transcription; and nitroimidazoles undergo reductive activation to form reactive species that cause physical damage to the bacterial DNA structure (PubMed: 11030693, 25643118, 22491334).